Literature DB >> 31280699

An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017).

Khary Adams1, Donna Clemons2, Lynn Collura Impelluso3, Donna Lee4, Sean Maguire5, Alexis Myers6, Christopher Petursson7, Robert Schulingkamp8, Kevin Trouba8, Matthew Wright9.   

Abstract

The recent Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on "The need for nonhuman primates in biomedical research, production and testing of products and devices" (2017 SCHEER) highlights approaches that could significantly contribute to the replacement, reduction, and refinement of nonhuman primate (NHP) studies. Initiatives that have the potential to affect NHP welfare and/or their use are expected to be appropriate, fair, and objective and publicly disseminated information focused on NHPs in biomedical research, which includes toxicologic and pathologic research and testing, should be objectively evaluated by stakeholder scientists, researchers, and veterinarians. Thus, IQ Consortium member companies convened to develop an informed and objective response, focusing on identifying areas of agreement, potential gaps, or missing information in 2017 SCHEER. Overall, the authors agree that many positions in the 2017 SCHEER Opinion generally align with industry views on the use of NHPs in research and testing, including the ongoing need of NHPs in many areas of research. From the perspective of the IQ Consortium, there are several topics in the 2017 SCHEER that merit additional comment, attention, or research, as well as consideration in future opinions.

Keywords:  (xeno)transplantation; DruSafe (IQ Consortium Preclinical Safety Leadership Group); IQ; SCHEER; biomedical research; infectious diseases; neuroscience; nonhuman primate; ophthalmology; safety; scientific Opinion; testing; toxicology; vaccines

Mesh:

Year:  2019        PMID: 31280699     DOI: 10.1177/0192623319857976

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  6 in total

1.  Evaluation of an enrichment programme for a colony of long-tailed macaques (Macaca fascicularis) in a rescue centre.

Authors:  Valeria Albanese; Michela Kuan; Pier Attilio Accorsi; Roberta Berardi; Giovanna Marliani
Journal:  Primates       Date:  2021-04-11       Impact factor: 2.163

2.  Revised recommendations for health monitoring of non-human primate colonies (2018): FELASA Working Group Report.

Authors:  Ivan Balansard; Lorna Cleverley; Keith L Cutler; Mats G Spångberg; Kevin Thibault-Duprey; Jan Am Langermans
Journal:  Lab Anim       Date:  2019-05-08       Impact factor: 2.471

3.  Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.

Authors:  Yazhou Li; Kelli L Vaughan; David Tweedie; Jin Jung; Hee Kyung Kim; Ho-Il Choi; Dong Seok Kim; Julie A Mattison; Nigel H Greig
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

4.  Protective cranial implant caps for macaques.

Authors:  Brook A L Perry; Stuart Mason; Jennifer Nacef; Ashley Waddle; Brian Hynes; Caroline Bergmann; Michael C Schmid; Christopher I Petkov; Alexander Thiele; Anna S Mitchell
Journal:  J Neurosci Methods       Date:  2020-10-29       Impact factor: 2.390

5.  Justification for species selection for pharmaceutical toxicity studies.

Authors:  Helen Prior; Richard Haworth; Briony Labram; Ruth Roberts; Alison Wolfreys; Fiona Sewell
Journal:  Toxicol Res (Camb)       Date:  2020-11-24       Impact factor: 3.524

6.  International primate neuroscience research regulation, public engagement and transparency opportunities.

Authors:  Anna S Mitchell; Renée Hartig; Michele A Basso; Wendy Jarrett; Sabine Kastner; Colline Poirier
Journal:  Neuroimage       Date:  2021-01-06       Impact factor: 6.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.